Study Population. The study population in this protocol is comprised of otherwise healthy ambulatory postmenopausal women who: 1. have participated in Study BA058-05-003, 2. were randomized to either BA058 Injection 80 µg/Placebo,
Appears in 1 contract
Samples: Clinical Trial Services Agreement (Radius Health, Inc.)
Study Population. The study population in this protocol is comprised of otherwise healthy ambulatory postmenopausal women who:
1. have participated in Study BA058-05-003, ,
2. were randomized to either BA058 Injection 80 µgAbaloparatide/Placebo,
3. have completed the End-of-Treatment Visit (Visit 9 in Study BA058-05-003), and
4. have provided a new written informed consent for this protocol. Subjects will not be enrolled if they experienced treatment-related SAE or were withdrawn from Study BA058-05-003 for any reason.
Appears in 1 contract
Samples: Clinical Trial Services Agreement (Radius Health, Inc.)
Study Population. The study population in this protocol is comprised of otherwise healthy ambulatory postmenopausal women who:
1. have participated in Study BA058-05-003, 2. were randomized to either BA058 Injection 80 µgAbaloparatide/Placebo,
Appears in 1 contract
Samples: Clinical Trial Services Agreement (Radius Health, Inc.)
Study Population. The study population in this protocol is comprised of otherwise healthy ambulatory postmenopausal women who:
1. have participated in Study BA058-05-003, ,
2. were randomized to either BA058 Injection 80 µg/Placebo,
3. have completed the End-of-Treatment Visit (Visit 9 in Study BA058-05-003), and
4. have provided a new written informed consent for this protocol. Subjects will not be enrolled if they experienced treatment-related SAE or were withdrawn from Study BA058-05-003 for any reason.
Appears in 1 contract
Samples: Clinical Trial Services Agreement (Radius Health, Inc.)